Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
In this prospective single arm study the investigators will assess the feasibility of S-1 and
Oxaliplatin as adjuvant treatment in patients with esophageal cancer.
The primary objective is to assess the feasibility of administering adjuvant S-1 and
Oxaliplatin (SOX) in patients with esophageal cancer after neoadjuvant chemoradiotherapy with
paclitaxel and carboplatin and esophagectomy. Primary end point is the percentage of patients
completing the preplanned number of 6 cycles of SOX.
Phase:
Phase 1
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)